What is Ocean Biomedical, Inc. (OCEA) stock price today?

Ocean Biomedical, Inc. (OCEA) is currently trading at $0.00.

What is OCEA P/E ratio?

Ocean Biomedical, Inc.'s P/E ratio is 0.00. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is OCEA return on equity (ROE)?

Ocean Biomedical, Inc.'s return on equity (ROE) is 3.06%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Ocean Biomedical, Inc.'s market cap?

Ocean Biomedical, Inc. has a market capitalization of $59318.

PNK · Biotechnology

Ocean Biomedical, Inc. (OCEA) Stock

$0.00 PNK: OCEA Healthcare

Valuation

Metric	Value
Price	$0.00
Market Cap	$59318
P/E Ratio	0.00
P/B Ratio	0.00
P/S Ratio	0.00
EPS (TTM)	$-0.12
52-Week High	$0.01
52-Week Low	$0.00
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	3.06%
ROA	-300.00%
ROCE	11.51%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	-0.16
Current Ratio	0.03

Annual Financials (USD)

Metric	2020	2021	2022	2023	2024
Revenue	$0	$0	$0	—	$0
Operating Profit	$-2.0M	$-1.0M	$-2.0M	—	$-4.0M
Net Profit	$-2.0M	$-62.0M	$1.0M	—	$-3.0M
EPS	$-0.08	$-0.04	$-0.05	—	$-0.12
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2020	2021	2022	2023	2024
Total Assets	$0	$109.0M	$111.0M	$6.0M	$1.0M
Total Liabilities	$2.0M	$3.0M	$7.0M	$96.0M	$99.0M
Cash	$0	$1.0M	$0	$0	$0
Borrowings	$0	$0	$2.0M	$12.0M	$16.0M

Cash Flow (USD)

Metric	2020	2021	2022	2023	2024
Operating Cash Flow	$0	$-1.0M	$-1.0M	$-9.0M	$-4.0M
Investing Cash Flow	$0	$-107.0M	$-2.0M	$0	$0
Financing Cash Flow	$0	$0	$0	$-12.0M	$0
Net Cash Flow	$0	$0	$-1.0M	$1.0M	$-1.0M
Free Cash Flow	$0	$-1.0M	$-1.0M	$-9.0M	$-4.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-2.17
FCF Yield	-7046.76%
Quick Ratio	0.02
Interest Coverage	1.86
Return 1Y	-98.48%
Return 3Y	-100.00%
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BACKIMAC Holdings, Inc.	$0.02	+0.00%	-0.01	$79484	0.00%
BCTXWBriaCell Therapeutics Corp.	$0.00	—	0.00	$1695	0.00%
CEROCERo Therapeutics Holdings, Inc.	$0.01	-7.69%	0.00	$14464	0.00%
KTTA	$0.45	-2.17%	-0.25	$3.35M	0.00%
NLSPNLS Pharmaceutics AG	$2.91	-12.61%	-0.43	$919601	0.00%

About Ocean Biomedical, Inc.

Ocean Biomedical, Inc. operates as a biopharmaceutical firm committed to identifying and advancing novel therapeutic solutions for various medical challenges, including cancer, fibrotic disorders, infectious illnesses, and inflammation. The company's pipeline includes the development of both mono-specific and bi-specific humanized monoclonal antibodies (mAbs). These candidates are specifically designed to target Chi3l1, offering potential treatments for non-small cell lung cancer and glioblastoma multiforme. Additionally, they are progressing a small molecule drug candidate aimed at Chit1, intended to address Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome. Leveraging its proprietary WPDS platform, Ocean Biomedical is also developing three further product candidates. These encompass a promising malaria vaccine, a humanized mAb therapeutic for malaria that targets the Plasmodium falciparum glutamic-acid-rich protein (PfGARP), and a small molecule malaria therapeutic also designed to interact with PfGARP. Furthermore, a treatment candidate for hospitalized COVID-19 patients is also under development. The company, established in 2019, maintains its operations in Providence, Rhode Island.

Ocean Biomedical, Inc. (OCEA) stock trades at $0.00 with a market capitalization of $59318. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.01, and currently trades 100.0% below its 52-week high.

On profitability, Ocean Biomedical, Inc. generates a return on equity (ROE) of 3.06%, return on capital employed of 11.51%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.oceanbiomedical.com